Article
Genome-wide association study identifies zonisamide responsive gene in Parkinson's disease patients.
Journal of human genetics - 1 Aug 2020
Cha Pei-Chieng, Satake Wataru, Ando-Kanagawa Yuko, Yamamoto Ken, Murata Miho, Toda Tatsushi
Abstract excerpt
Long-term treatment of Parkinson's disease (PD) by levodopa leads to motor complication "wearing-off". Zonisamide is a nondopaminergic antiparkinsonian drug that can improve "wearing-off" although response to the treatment varies between individuals. To clarify the genetic basis of zonisamide responsiveness, we conducted a genome-wide association study (GWAS) on 200 PD patients from a placebo-controlled clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.